Status:
ACTIVE_NOT_RECRUITING
Deep Learning Model and Risk Factors for Tacrolimus-related Acute Kidney Injury
Lead Sponsor:
Qianfoshan Hospital
Conditions:
AKI
Eligibility:
All Genders
18+ years
Brief Summary
In this study, the investigators aim to develop a risk prediction model for acute kidney injury (AKI) in hospitalized patients using the calcineurin inhibitor tacrolimus. This will be achieved by mini...
Eligibility Criteria
Inclusion
- Use of tacrolimus during hospitalization, with standardized therapeutic drug monitoring
- Age of 18 years or older at the time of admission
- Length of hospital stay ≥ hours
- At least two serum creatinine level tests conducted during the hospital stay
Exclusion
- Stage 5 chronic kidney disease prior to admission
- Incomplete clinical data
- Serum creatinine levels consistently below 40 mmol/L during hospitalization
Key Trial Info
Start Date :
September 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2026
Estimated Enrollment :
1200 Patients enrolled
Trial Details
Trial ID
NCT06596798
Start Date
September 1 2024
End Date
December 30 2026
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital
Jinan, Shandong, China, 250014